WallStSmart

Lixte Biotechnology Holdings Inc (LIXT)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

LIXT leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

LIXT

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.8
Piotroski: 3/9

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LIXT.

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIXT1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

LIXT4 concerns · Avg: 3.8/10
Price/BookValuation
10.6x4/10

Trading at 10.6x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$133.35M3/10

Smaller company, higher risk/reward

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : LIXT

The strongest argument for LIXT centers on Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : LIXT

The primary concerns for LIXT are Price/Book, Revenue Growth, EPS Growth.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

LIXT profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

LIXT carries more volatility with a beta of 1.28 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

LIXT generates stronger free cash flow (-2M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 16/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lixte Biotechnology Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets related to serious common diseases and designs novel compounds to attack those targets. The company is headquartered in East Setauket, New York.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?